JNJ-10198409

Description: JNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM). JNJ-10198409 has good activity against PDGFR-beta kinase (IC50=4.2 nM) and PDGFR-alpha kinase (IC50=45 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. Target: PDGFR. Smiles: COc1cc2Cc3c(Nc4cccc(F)c4)n[nH]c3-c2cc1OC. References: D'Andrea MR, et al. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther. 2005 Aug,4(8):1198-204.